RxDoctor Payments Data

Haylee Goad

Family · Noblesville, INNPI 1417626409

Payments from drug & device makers

$3,815in general payments, 2019–2025

Across 106 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$966
  • Curonix LLC$606
  • Collegium Pharmaceutical, Inc.$295
  • Boston Scientific$270
  • Averitas Pharma Inc.$260
  • Johnson & Johnson$226
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,28234%
  • Food & beverage$2,53366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,815 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$16,984
Medicare patients
83
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,140$32,509
LinzessLinaclotide48$28,237
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen682$24,753
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl139$19,058
Buprenorphine57$18,501
BelbucaBuprenorphine Hcl20$18,487
NucyntaTapentadol Hcl14$13,905
Nucynta ErTapentadol Hcl12$10,597
Xtampza ErOxycodone Myristate14$10,527
Hysingla ErHydrocodone Bitartrate18$10,180
Pregabalin286$8,364
Fentanyl30$6,985
OxycontinOxycodone Hcl16$6,586
Lidocaine61$4,886
Morphine Sulfate ErMorphine Sulfate177$4,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er, Xtampza Er$295$53,51660 claims
AbbVieLinzess$43$28,23748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →